What's New
| Page summary | Text size | Search | |
What’s New keeps you up-to-date with the latest InCirculation.net activities.
| | |
24 August 2010Dual antiplatelet therapy is the cornerstone of the treatment of acute coronary syndromes with or without stent implantation, but what is the optimal duration of this therapy? Freek Verheugt discusses long-awaited data from two randomized studies – REAL-LATE and ZEST-LATE – that go some way to answering this question. 15 April 2010Optimal antiplatelet therapy is a delicate balance between efficacy and safety, but new inhibitors of platelet activity might provide better protection against thrombotic events and are associated with less risk of bleeding than with clopidogrel or aspirin. Jurriën ten Berg reviews the field and the novel techniques that are leading us ever closer to a truly personalized medical approach.
27 November 2009The PLATO trial enveiled ticagrelor as the first antiplatelet therapy to achieve a significant reduction in CV mortality compared with clopidogrel across the spectrum of ACS. Freek Verheugt reviews the field - CURE, COMMIT, TRITON-TIMI 38 and the CHAMPION trials. Did PLATO herald a new dawn in antiplatelet therapy?
| |
